AU2015203433B2 - Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells - Google Patents
Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells Download PDFInfo
- Publication number
- AU2015203433B2 AU2015203433B2 AU2015203433A AU2015203433A AU2015203433B2 AU 2015203433 B2 AU2015203433 B2 AU 2015203433B2 AU 2015203433 A AU2015203433 A AU 2015203433A AU 2015203433 A AU2015203433 A AU 2015203433A AU 2015203433 B2 AU2015203433 B2 AU 2015203433B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- cell
- diacrylate
- derived
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 50
- 210000004248 oligodendroglia Anatomy 0.000 title claims description 23
- 238000012258 culturing Methods 0.000 title description 13
- 238000004113 cell culture Methods 0.000 claims description 20
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 17
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 15
- -1 Oligl Proteins 0.000 claims description 14
- 239000002861 polymer material Substances 0.000 claims description 12
- 102000008730 Nestin Human genes 0.000 claims description 6
- 108010088225 Nestin Proteins 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 210000005055 nestin Anatomy 0.000 claims description 6
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 4
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 69
- 239000000178 monomer Substances 0.000 description 66
- 239000010410 layer Substances 0.000 description 31
- 239000002904 solvent Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000000463 material Substances 0.000 description 27
- 229920001059 synthetic polymer Polymers 0.000 description 27
- 238000000576 coating method Methods 0.000 description 21
- 125000004386 diacrylate group Chemical group 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000000758 substrate Substances 0.000 description 17
- 229920001577 copolymer Polymers 0.000 description 13
- 108010082117 matrigel Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 230000036755 cellular response Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003999 initiator Substances 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 7
- 229920001519 homopolymer Polymers 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- XFCMNSHQOZQILR-UHFFFAOYSA-N 2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOC(=O)C(C)=C XFCMNSHQOZQILR-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 6
- 239000003504 photosensitizing agent Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000011536 re-plating Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- HCLJOFJIQIJXHS-UHFFFAOYSA-N 2-[2-[2-(2-prop-2-enoyloxyethoxy)ethoxy]ethoxy]ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOCCOCCOC(=O)C=C HCLJOFJIQIJXHS-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- UKMBKKFLJMFCSA-UHFFFAOYSA-N [3-hydroxy-2-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)OC(=O)C(C)=C UKMBKKFLJMFCSA-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- YDKNBNOOCSNPNS-UHFFFAOYSA-N methyl 1,3-benzoxazole-2-carboxylate Chemical compound C1=CC=C2OC(C(=O)OC)=NC2=C1 YDKNBNOOCSNPNS-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000009832 plasma treatment Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- BWTMTZBMAGYMOD-UHFFFAOYSA-N (2,2,3,3,4,4,5,5-octafluoro-6-prop-2-enoyloxyhexyl) prop-2-enoate Chemical compound C=CC(=O)OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)COC(=O)C=C BWTMTZBMAGYMOD-UHFFFAOYSA-N 0.000 description 3
- PSSYEWWHQGPWGA-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-prop-2-enoyloxypropoxy)propoxy]propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(O)COCC(O)COCC(O)COC(=O)C=C PSSYEWWHQGPWGA-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 229920005650 polypropylene glycol diacrylate Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- XOJWAAUYNWGQAU-UHFFFAOYSA-N 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCOC(=O)C(C)=C XOJWAAUYNWGQAU-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BMMOLQBKUNREMW-UHFFFAOYSA-N C(CCCCCO)O.C(C(=C)C)(=O)OCC(OC(C(=C)C)=O)CO Chemical compound C(CCCCCO)O.C(C(=C)C)(=O)OCC(OC(C(=C)C)=O)CO BMMOLQBKUNREMW-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000028419 Styrax benzoin Species 0.000 description 2
- 235000000126 Styrax benzoin Nutrition 0.000 description 2
- 235000008411 Sumatra benzointree Nutrition 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- ULQMPOIOSDXIGC-UHFFFAOYSA-N [2,2-dimethyl-3-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(C)(C)COC(=O)C(C)=C ULQMPOIOSDXIGC-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960002130 benzoin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000019382 gum benzoic Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- QNODIIQQMGDSEF-UHFFFAOYSA-N (1-hydroxycyclohexyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1(O)CCCCC1 QNODIIQQMGDSEF-UHFFFAOYSA-N 0.000 description 1
- REKKSQKKPJWAGD-UHFFFAOYSA-N (2,2-dimethyl-3-prop-2-enoyloxypropyl) prop-2-enoate;hexane-1,6-diol Chemical compound OCCCCCCO.C=CC(=O)OCC(C)(C)COC(=O)C=C REKKSQKKPJWAGD-UHFFFAOYSA-N 0.000 description 1
- SZCWBURCISJFEZ-UHFFFAOYSA-N (3-hydroxy-2,2-dimethylpropyl) 3-hydroxy-2,2-dimethylpropanoate Chemical compound OCC(C)(C)COC(=O)C(C)(C)CO SZCWBURCISJFEZ-UHFFFAOYSA-N 0.000 description 1
- FNYSXXARASJZSL-UHFFFAOYSA-N 2,2-bis(prop-2-enoyloxymethyl)butyl benzoate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C1=CC=CC=C1 FNYSXXARASJZSL-UHFFFAOYSA-N 0.000 description 1
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
- LBWXXEPSNAQRLY-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diol 6-prop-2-enoyloxyhexyl prop-2-enoate Chemical compound OCC(C)(CO)C.C(C=C)(=O)OCCCCCCOC(C=C)=O LBWXXEPSNAQRLY-UHFFFAOYSA-N 0.000 description 1
- ZUCZTOKYCDKFJF-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diol;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O.OCC(C)(C)CO ZUCZTOKYCDKFJF-UHFFFAOYSA-N 0.000 description 1
- LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 1
- KJSGODDTWRXQRH-UHFFFAOYSA-N 2-(dimethylamino)ethyl benzoate Chemical compound CN(C)CCOC(=O)C1=CC=CC=C1 KJSGODDTWRXQRH-UHFFFAOYSA-N 0.000 description 1
- VIIZJXNVVJKISZ-UHFFFAOYSA-N 2-(n-methylanilino)ethanol Chemical compound OCCN(C)C1=CC=CC=C1 VIIZJXNVVJKISZ-UHFFFAOYSA-N 0.000 description 1
- SBOXDRICSJHEBA-UHFFFAOYSA-N 2-[2-(2-methoxyethoxymethyl)-2-(2-prop-2-enoyloxyethoxymethyl)butoxy]ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCC(COCCOC)(CC)COCCOC(=O)C=C SBOXDRICSJHEBA-UHFFFAOYSA-N 0.000 description 1
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 description 1
- UHFFVFAKEGKNAQ-UHFFFAOYSA-N 2-benzyl-2-(dimethylamino)-1-(4-morpholin-4-ylphenyl)butan-1-one Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(=O)C(CC)(N(C)C)CC1=CC=CC=C1 UHFFVFAKEGKNAQ-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- VJZQKOYTXILEMT-UHFFFAOYSA-N 2-methylprop-2-enoic acid 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O.CC(=C)C(=O)OCCCCOC(=O)C(C)=C VJZQKOYTXILEMT-UHFFFAOYSA-N 0.000 description 1
- ZAFWTFZPSFHMKE-UHFFFAOYSA-N 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate 9-prop-2-enoyloxynonyl prop-2-enoate Chemical compound C(C=C)(=O)OCCCCCCCCCOC(C=C)=O.C(C(=C)C)(=O)OCCCCOC(C(=C)C)=O ZAFWTFZPSFHMKE-UHFFFAOYSA-N 0.000 description 1
- RTNUTCOTGVKVBR-UHFFFAOYSA-N 4-chlorotriazine Chemical class ClC1=CC=NN=N1 RTNUTCOTGVKVBR-UHFFFAOYSA-N 0.000 description 1
- FIHBHSQYSYVZQE-UHFFFAOYSA-N 6-prop-2-enoyloxyhexyl prop-2-enoate Chemical compound C=CC(=O)OCCCCCCOC(=O)C=C FIHBHSQYSYVZQE-UHFFFAOYSA-N 0.000 description 1
- FKNJCFIGMJDWHA-UHFFFAOYSA-N 6-prop-2-enoyloxyhexyl prop-2-enoate [2-(prop-2-enoyloxymethyl)-1-tricyclo[5.2.1.02,6]decanyl]methyl prop-2-enoate Chemical compound C=CC(=O)OCCCCCCOC(=O)C=C.C=CC(=O)OCC12CCC(C1)C1CCCC21COC(=O)C=C FKNJCFIGMJDWHA-UHFFFAOYSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 229940076442 9,10-anthraquinone Drugs 0.000 description 1
- PGDIJTMOHORACQ-UHFFFAOYSA-N 9-prop-2-enoyloxynonyl prop-2-enoate Chemical compound C=CC(=O)OCCCCCCCCCOC(=O)C=C PGDIJTMOHORACQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101000993093 Arabidopsis thaliana Heat stress transcription factor B-2a Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DNEYQSGIZJGDMF-UHFFFAOYSA-N C(C(=C)C)(=O)OCCOCCOCCOCCOC(C(=C)C)=O.C(C(=C)C)(=O)OCC(OC(C(=C)C)=O)CO Chemical compound C(C(=C)C)(=O)OCCOCCOCCOCCOC(C(=C)C)=O.C(C(=C)C)(=O)OCC(OC(C(=C)C)=O)CO DNEYQSGIZJGDMF-UHFFFAOYSA-N 0.000 description 1
- SFOBEUAYVINGNM-UHFFFAOYSA-N C(C=C)(=O)O.C(C=C)(=O)O.C(C=C)(=O)O.C(O)C(CC)(CO)CO.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O Chemical compound C(C=C)(=O)O.C(C=C)(=O)O.C(C=C)(=O)O.C(O)C(CC)(CO)CO.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O SFOBEUAYVINGNM-UHFFFAOYSA-N 0.000 description 1
- GQKYQZOYCJTQPU-UHFFFAOYSA-N C(CCCCCO)O.C(C=C)(=O)OCCCCCCOC(C=C)=O Chemical compound C(CCCCCO)O.C(C=C)(=O)OCCCCCCOC(C=C)=O GQKYQZOYCJTQPU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 101710190344 Heat shock factor protein 1 Proteins 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101150029234 Hes5 gene Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- XRXQEKQKIDONIS-UHFFFAOYSA-N OCC(C)(CO)C.C(C=C)(=O)O.C(C=C)(=O)O.CO Chemical compound OCC(C)(CO)C.C(C=C)(=O)O.C(C=C)(=O)O.CO XRXQEKQKIDONIS-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NGWVVENDFMHRFT-UHFFFAOYSA-N acetic acid;furan-2,5-dione Chemical compound CC(O)=O.O=C1OC(=O)C=C1 NGWVVENDFMHRFT-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000008365 aromatic ketones Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000005410 aryl sulfonium group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229920006334 epoxy coating Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- YSVJDJBOLBXSIT-UHFFFAOYSA-N methanol prop-2-enoic acid Chemical compound OC.OC(=O)C=C.OC(=O)C=C YSVJDJBOLBXSIT-UHFFFAOYSA-N 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- WVIICGIFSIBFOG-UHFFFAOYSA-N pyrylium Chemical class C1=CC=[O+]C=C1 WVIICGIFSIBFOG-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- YRHRIQCWCFGUEQ-UHFFFAOYSA-N thioxanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3SC2=C1 YRHRIQCWCFGUEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED OLIGODENDROCYTE PROGENITOR CELLS 2015203433 22 Jun2015
This is a divisional of AU 2009209167, the entire contents of which are incorporated herein by reference.
PRIORITY
[0001] This application claims priority to US provisional Appl. No. 61/063,010, filed January 30, 2008, and is incorporated by reference in its entirety.
FIELD
[0002] The present disclosure relates to cell culture articles and methods of use thereof, and more particularly to articles for supporting the culture of stem cell derived oligodendrocyte progenitor cells.
BACKGROUND
[0003] Pluripotent stem cells, such as human embryonic stem cells (hESCs) have the ability to differentiate into any of the three germ layers, giving rise to any adult cell type in the human body. This unique property provides a potential for developing new treatments for a number of serious cell degenerative diseases, such as diabetes, spinal cord injury, heart disease and the like. For example, spinal cord damage is generally irreversible with current treatments, leaving approximately 250,000 Americans in a devastating position. However, as stem cell research has developed, new exciting possibilities have arisen for people suffering from spinal cord injury. ES cell-derived neural cells have been used by researchers to treat nervous system disorders in animal models. In earlier work, researchers showed that mouse ES cells could be stimulated to differentiate into neural cells that, when transplanted into mice with neurological disorders, helped to restore normal function.
[0004] However there remain obstacles in the development of such hESC-based treatments. Such obstacles include obtaining and maintaining adequate numbers of undifferentiated hESCs in tissue culture and controlling their differentiation in order to produce specific cell types. Stem cell cultures, such as hESC cell cultures are typically seeded with a small 1 number of cells from a cell bank or stock and then amplified in the undifferentiated state until differentiation is desired for a given therapeutic application To accomplish this, the hESC or their differentiated cells are currently cultured in the presence of surfaces or media containing animal-derived components, such as feeder layers, fetal bovine serum, or MATRIGEL®. These animal-derived additions to the culture environment expose the cells to potentially harmful viruses or other infectious agents which could be transferred to patients or compromise general culture and maintenance of the hESCs. In addition, such biological products are vulnerable to batch variation, immune response and limited shelf-life. 2015203433 22 Jun2015 [0005] Some steps have been taken to culture hESCs either in media or on surfaces that are free of animal-derived components. However, the response of hESCs or their differentiated derivatives is difficult to predict as components of the surface or culture medium change. Yet some advances have been made. For example, hESC-derived oligodendrocyte progenitor cells (OPCs) have been cultured in defined serum-free medium. While such culture systems are not completely xeno-free culture systems when the matrices employed contain animal-derived components, such as gelatin and MATRIGEL, they do provide a step toward the eventual clinical application of hESC-derived OPCs. By way of further example, some synthetic surfaces have been identified that can support differentiation of human epithelial stem cells into epithelial cells. However, the systems employed relied on serum medium for the cell culture, which still potentially causes problem as described before for all biological animal derived components. To date, a completely animal free system employing a chemically defined medium and a synthetic surface has not yet been identified for culturing stem cells or cells derived from stem cells.
BRIEF SUMMARY
[0006] The present disclosure describes, inter alia, synthetic surfaces useful in the culture of stem cell-derived OPCs in chemically defined media.
[0007] In an embodiment, a method for culturing oligodendrocyte progenitor cells is provided. The method includes depositing a suspension containing the oligodendrocyte progenitor 2 cells on a polymer material and: culturing the deposited oligodendrocyte progenitor cells in a cell culture medium. The polymer material comprises a homopolymer or copolymer of selected one or more acrylate monomers. 2015203433 08 Mar 2017 [0008] In an embodiment, a culture of oligodendrocyte progenitor cells is provided. The culture includes an article having a polymer material disposed on a surface. The culture further includes the oligodendrocyte progenitor cells disposed on the polymer material and a culture medium in which the oligodendrocyte progenitor cells are cultured. The polymer material comprises: a homopolymer or copolymer of selected one- or more acrylate monomers.
[00O§A] In one example, a cell culture according to the present disclosure is provided, wherein the oligodendrocyte progenitor cell expresses one or more markers selected from Nestin, Oligl, platelet derived growth factor receptor alpha {PDGFRaj and NG2.
[0009] In an embodiment, a cell culture article for culturing oligodendrocyte progenitor cells in a chemically defined medium is provided. The article includes a substrate having a surface and a polymer material disposed on the surface. The polymer material comprises a homopolymer or copolymer of selected one or more acrylate monomers.
One or more of the various embodiments presented herein provide one or more advantages over prior surfaces for culturing stem cell-derived OPCs. For example, the synthetic surfaces reduce potential contamination issues associated with surfaces having components obtained from or derived from animal sources. Such surfaces may also provide for improved shelf life compared to those surfaces with biological components. The ability to culture stem cell-derived OPCs in chemically-defined media further reduces potential contamination issues, In addition, there will likely be less batch to batch variation in the ability of the synthetic surfaces or chemically defined media, resulting in improved reproducibility of culture results and expectations. These and other advantages will be readily understood from the following detailed descriptions when, read in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS 00111 FIGs. 1A-B are schematic diagrams of side views of synthetic polymer layer coated articles. 0012] FIG. 2A-C are schematic diagrams of cross sections of cell culture articles having a well. Uncoated (2A); coated surface (2B); and coated surface and side walls (2C). 2015203433 22 Jun2015 0013] FIGs. 3A-C are fluorescence images of immunostained hES cell-derived OPCs after replating on acrylate coating surface 123-2 (A) and 95-2 (B), and positive control surface Matrigel (C) between 28-day and 35-day. OPCs derived from human ES cells were immunostained for the OPC marker, Oligl (green) and nestin (red). 0014] FIGs. 4A-C are fluorescence images of immunostained hES cell-derived OPCs after replating on acrylate coated surface 123-2 (A), 122-3 (B) and Matrigel™ (C) between 28-day and 35-day as well as between 35-day and 42-day. OPCs derived from human ES cells were immunostained for the OPC marker, Oligl (green) and nestin (red). 0015] FIGs. 5A-F are fluorescence images of hES cell-derived OPCs on Matrigel™ (A) and on acrylate coated surfaces 22-2 (B), 22-3 (C), 133-4 (D), 24-10 (E), and 72-2 (F). 0016] The drawings are not necessarily to scale. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar.
DETAILED DESCRIPTION
[0017] In the following detailed description, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration several specific embodiments of devices, systems and methods. It is to be understood that other embodiments are contemplated and may be made without departing from the scope or spirit of the present disclosure. The following detailed description, therefore, is not to be taken in a limiting sense.
[0018] All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding 4 2015203433 08 Mar 2017 of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
[0019] As used in this specification and the appended claims, the singular forms "a", "an", and "the” encompass embodiments having plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims» the term "or” is generally employed in its sense including "and/or” unless the content clearly dictates otherwise.
[0020] Unless stated otherwise, ratios of compounds in a composition, such as a solution, are stated on a by volume basis.
[0021] As used herein, "have", "having", "include", "including", "comprise", "comprising" or the like are used in their open ended sense, and generally mean "including, but not limited to".
[0021 A] Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0022] The present disclosure describes, inter alia, articles having synthetic surfaces for culturing stem cell-derived OPCs and methods for culturing stem cell-derived OPCs on such surfaces. In some embodiments, the synthetic surfaces are used in combination with a chemically defined medium to culture stem cell-derived OPCs. The surfaces may be useful in differentiating stem cells, such as hESCs, into OPCs or for proliferating such stem cell-derived OPCs, [0022A] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application. 5 2015203433 08 Mar 2017 [0023] 1. Cell Culture Article [0024] Referring to FIG. 1, a schematic, diagram of article 100 for culturing cells is shown. The article 100 includes a base material substrate 10 having a surface 15. A synthetic polymer coating layer 20 is disposed on the surface 15 of the base material 10, While not shown, it will be understood that synthetic polymer coating 20 may be disposed on a portion of base material 10. The base material 10 may be any material suitable for culturing cells, including a ceramic substance, a glass, a plastic, a polymer or copolymer, any combinations thereof, or a coating of one material on another. Such base materials 10 include glass materials such as soda-lime glass, pyrex glass, vycor glass, quartz glass; silicon; plasties or polymers, including dendritic polymers, such as poly(vmyl chloride), poiy(vinyl alcohol), polytmethyl methacrylate), polyivinyl acetate-maleic anhydride), poly(dimethyisiloxane) monomethacryiate, cyclic olefin polymers, fluorocarbon polymers, polystyrenes, polypropylene, polyethyleneimine; copolymers such as poly(vinyl acetate-co-maleic anhydride), poly(styrene-co-maleic anhydride), poly(ethylene-co-acrylic acid) or derivatives of these or the like. 2015203433 22 Jun2015 0025] Examples of articles 100 suitable for cell culture include single and multi-well plates, such as 6, 12, 96, 384, and 1536 well plates, jars, petri dishes, flasks, beakers, plates, roller bottles, slides, such as chambered and multichambered culture slides, tubes, cover slips, cups, spinner bottles, perfusion chambers, bioreactors, CellSTACKs® and fermenters. 0026] Synthetic polymer coating 20 provides a surface 25 on which cells may be cultured. The synthetic polymer surface 20 includes polymerized acrylate monomers, selected from the group of monomers provided in Table 1 below. Other materials (not shown), such as peptides, may be incorporated into or conjugated to synthetic polymer surface to produce a biomimetic surface.
Table 1: List of acrylate monomers
Monomer name Monomer structure Tetra(ethylene glycol) diacrylate ( M ) { h2c=ch-c-och2 ch2 och2 ch2y 2 o Glycerol dimethacrylate CH, O OH O CH, 1 3 II 1 II 1 h2c=c-—c —o ch2 chch2 o—c—c=ch2 Triethylene glycol dimethacrylate O 0 CH, II 11 1 H,C=C-C- (OCK, CH2 )30-C-C=CH2 ch3 1,4-Butanediol dimethacrylate 0 o II II h2c=c-c-och2 ch2 ch2 ch2o-c-c=ch2 ch3 ch3 6 2015203433 22 Jun2015
Poly(ethylene glycol) diacrylate, Mn~258 o 0 M / \ H H2C = CH-C-(-OCH2CH2 -4—o—c—ch = ch2 1,6-Hexanediol diacrylate ( " ) \ h2c=ch-c-och2 ch2 ch2 -J2 3-Hydroxy-2,2-dimethylpropyl 3-hydroxy -2,2-dimethylpropionate 0 CH, 0 CH, O II 1 II 1 II H,C = CH-C-0 CH, -C —C-OCH, -C-CH, 0-C-CH = CH, 1 1 ch3 ch3 Neopentyl glycol propoxylate (1PO/OH) diacrylate O CH, O II 1 II H2C=CH-C-0 (C;.HeO)m CH, -C-CHj (OC3H.)n 0-C-CH=CH3 CH3 in + n ~ 2 Di(ethylene glycol) diacrylate O O II II h2c=ch-c-och2 ch2 och2 ch2 o-c-ch=ch2 Di(ethylene glycol) dimethacrylate o o II II h2c=c-c-och2 ch2 och2 ch2 o-c-c=ch2 ch3 ch3 Tetra(ethylene glycol) dimethacrylate CH, 0 0 CH, 1 3 II IIId H2C=C—C-OCH-, ch2 och2 ch2 och2 ch2 och2 ch2 0-C-C = ( 1,6-Hexanediol propoxylate diacrylate o 11 i \ H2C = CH-C-0-~C3H6 O-j-CHj ch2 ch2 , 1 n I H-C~-CH — c — 0-2-C„Hc O VchL ChL CH,, 2 || \ i * / Z 2 2 0 n Glycerol 1,3-diglycerolate diacrylate 0 0 II II H2C=CH-C-0CHj chch2 och2 chch2 och2 chch2 0-C-CH = CHj OH OH OH Neopentyl glycol diacrylate 0 ch3 0 II 1 II H2C-CH C OCH, c ch2o c ch-ch2 ch3 7 2015203433 22 Jun2015
Neopentyl glycol dimethacrylate O CH. 0 II 1 II h2c=c-c-och, — c—ch2 o-c-c=ch2 2 I 2 ! 2 ! 2 CHS CH3 CH3 Trimethylolpropane benzoate diacrylate O CH2CH» O II 1 II H2C = CH-C-OCH2 — C — CH2 O — c —ch—ch2 T rimethylolpropane ethoxylate (1 EO/OH) methyl 0 II h2c = ch—c—0CH2 CH2 OCH2 c h3oc h2c h,oc h2 - cch2ch3 o ‘ I ii 1 h2c= ch—c—och2 ch2 och2 T ricyclo [5.2.1.02,6] decanedi methanol diacrylate Neopentyl glycol ethoxylate diacrylate 0 h3c ch3 0 T rimethylolpropane triacrylate 0 II h2c=ch-c-och2 ο 1 μ 1 h2c=ch-c-och2 -c-ch2ch3 o ii 1 H2C=CH“C-OCH2 1,6-Hexanediol ethoxylate diacrylate Mn ~314 0 H2C —CH —C —0—^CH2 CH2 0-^—CH2 CH, ch, 0 " | H2C = CH-C —0—^CH2CH20^-CH2CH2 ch2 2,2,3,3,4,4,5,5 octafluoro 1, 6 hexanediol diacrylate F. F F, F 9 0 F F F F Polypropylene glycol) diacrylate o o II / \ II H C = CH-C-(-OC3H6 -^0-C-CH”CH2 \ / n n-7 1,9 nonanediol diacrylate 8 2015203433 22 Jun2015 0027] The acrylates listed in Table 1 may be synthesized as known in the art or obtained from a commercial vendor, such as Polysciences, Inc., Sigma Aldrich, Inc., and Sartomer, Inc. 0028] As shown in FIG. IB, an intermediate layer 30 may be disposed between surface 15 of base material 10 and the synthetic polymer coating 20. Intermediate layer 30 may be configured to improve binding of coating 20 to substrate 10, to facilitate monomer spreading, to render portions of the surface 10 that are uncoated cytophobic to encourage cell growth on coated areas, to provide a substrate compatible with a monomer or solvent where the monomer or solvent is incompatible with the base material 10, to provide topographical features if desired through, for example, patterned printing, or the like. For example, if substrate 10 is a glass substrate, it may be desirable to treat a surface of the glass substrate with a silane molecule or an epoxy coating. For various polymer base materials 10 it may be desirable to provide an intermediate layer 30 of polyamide, polyimide, polypropylene, polyethtylene, or polyacrylate. While not shown, it will be understood that synthetic polymer coating 20 may be disposed on a portion of intermediate layer 30. It will be further understood that intermediate layer 30 may be disposed on a portion of base material 10. 0029] In various embodiments, surface 15 of base material 10 is treated, either physically or chemically, to impart a desirable property or characteristic to the surface 15. For example, and as discussed below, surface 15 may be corona treated or plasma treated. Examples of vacuum or atmospheric pressure plasma include radio frequency (RF) and microwave plasmas both primary and secondary, dielectric barrier discharge, and corona discharge generated in molecular or mixed gases including air, oxygen, nitrogen, argon, carbon dioxide, nitrous oxide, or water vapor.
[0030] Synthetic polymer coating layer 20, whether disposed on an intermediate layer 30 or base material 10, preferably uniformly coats the underlying substrate. By “uniformly coated”, it is meant that the layer 20 in a given area, for example a surface of a well of a culture plate, completely coats the area at a thickness of about 5 nm or greater. While the thickness of a uniformly coated surface may vary across the surface, there are no areas of the uniformly coated surfaces through which the underlying layer (either intermediate 9 layer 30 or base material 10) is exposed. Cell responses across non-uniform surfaces tend to be more variable than cell responses across uniform surfaces. 2015203433 22 Jun2015 0031] Synthetic polymer coating layer 20 may have any desirable thickness. However, it has been found that thicker coatings, e.g. coatings of greater than about 10 micrometers, tend to have unevenness around the periphery of the coating due to surface tension. In various embodiments, the thickness of the coating layer 20 is less than about 10 micrometers. For example, the thickness may be less than about 5 micrometers, less than about 2 micrometers, less than about 1 micrometers, less than about 0.5 micrometers or less than about 0.1 micrometers. 0032] The polymer material forming synthetic polymer layer 20 may be cross-linked to any suitable degree. Higher degrees of cross-linking may result in reduced waste product and reduced cell toxicity. 0033] Article 100, in numerous embodiments, is cell culture ware having a well, such as a petri dish, a multi-well plate, a flask, a beaker or other container having a well. Referring now to FIG. 2, article 100 formed from base material 10 may include one or more wells 50. Well 50 includes a sidewall 55 and a surface 15. Referring to FIG. 2B-C, a synthetic polymer coating 20 may be disposed on surface 15 or sidewalls 55 (or, as discussed above with regard to FIG. 1 one or more intermediate layer 30 may be disposed between surface 15 or sidewall 55 and synthetic polymer coating 20) or a portion thereof. 0034] In various embodiments, article 100 includes a uniformly coated layer 20 having a surface 25 with an area greater than about 5 mm2. When the area of the surface 15 is too small, reliable cell responses may not be readily observable because some cells, such as human embryonic stem cells, are seeded as colonies or clusters of cells (e.g., having a diameter of about 0.5 mm) and adequate surface is desirable to ensure attachment of sufficient numbers of colonies to produce a quantitative cell response. In numerous embodiments, an article 100 has a well 50 having a uniformly coated surface 15, where the surface 15 has an area greater than about 0.1 cm2, greater than about 0.3 cm2, greater than about 0.9 cm , or greater than about 1cm .
[0035] 2. Coating of Synthetic Polymer Layer 10 0036] A synthetic polymer layer may be disposed on a surface of a cell culture article via any known or future developed process. Preferably, the synthetic polymer layer provides a uniform layer that does not delaminate during typical cell culture conditions. The synthetic polymer surface may be associated with the base material substrate via covalent or non-covalent interactions. Examples of non-covalent interactions that may associate the synthetic polymer surface with the substrate include chemical adsorption, hydrogen bonding, surface interpenetration, ionic bonding, van der Waals forces, hydrophobic interactions, dipole-dipole interactions, mechanical interlocking, and combinations thereof. 2015203433 22 Jun2015 [0037] In various embodiments, the base material substrate surface is coated according to the teachings of co-pending application serial no._, filed on even date herewith, naming Gehman et al. as inventors, having attorney docket number 20726, and entitled STEM CELL CULTURE ARTICLE AND SCREENING, which is hereby incorporated herein by reference in its entirety for all purposes to the extent that it does not conflict with the disclosure presented herein.
[0038] In numerous embodiments, monomers are deposited on a surface of a cell culture article and polymerized in situ. In such embodiments, the base material will be referred to herein as the “substrate” on which the synthetic polymer material is deposited. Polymerization may be done in solution phase or in bulk phase.
[0039] As many of the monomers identified in Table 1 above are viscous, it may be desirable to dilute the monomers in a suitable solvent to reduce viscosity prior to being dispensed on the surface. Reducing viscosity may allow for thinner and more uniform layers of the synthetic polymer material to be formed. One of skill in the art will be able to readily select a suitable solvent. Preferably the solvent is compatible with the material forming the cell culture article and the monomers. It may be desirable to select a solvent that is non-toxic to the cells to be cultured and that does not interfere with the polymerization reaction. Alternatively, or in addition, selection of a solvent that can be substantially completely removed or removed to an extent that it is non-toxic or no longer interferes with polymerization may be desirable. In additional embodiments, it may be desirable to select solvents which do not interact with the substrate. Further, it may be desirable that the solvent be readily removable without harsh conditions, such as vacuum or extreme heat. Volatile solvents are examples of such readily removable solvents. As described in 11 co-pending application serial no._, ethanol may be a particularly suitable 2015203433 22 Jun2015 solvent when it is desired to remove solvent prior to polymerization.
[0040] [0041] [0042]
The monomers may be diluted with solvent by any suitable amount to achieve the desired viscosity and monomer concentration. Generally the monomer compositions used according to the teachings presented herein contain between about 0.1% to about 99% monomer. By way of example, the monomer may be diluted with an ethanol solvent to provide a composition having between about 0.1% and about 50% monomer, or from about 0.1% to about 10% monomer by volume. The monomers may be diluted with solvent so that the polymer layer 20 achieves a desired thickness. As discussed above, if the deposited monomers are too thick, an uneven surface may result. As described in further details in the Examples, uneven surfaces may be observed when the monomer-solvent composition is deposited on a surface 15 of a well 50 at a volume of greater than about 8 microliters per square centimeter of the surface 15. In various embodiments, the monomer-solvent compositions are deposited on a surface 15 of a well 50 in a volume of about 7 microliters or less per square centimeter of the surface 15. For example, the monomer-solvent compositions may be deposited on a surface 15 of a well 50 in a volume of about 5 microliters or less per square centimeter of the surface 15, or about 2 microliters or less per square centimeter of the surface 15.
In various embodiments, article 100 includes a uniformly coated layer 20 having a surface 25 with an area greater than about 5 mm2. When the area of the surface 15 is too small, reliable cell responses may not be readily observable because some cells, such as human embryonic stem cells, are seeded as colonies or clusters of cells (e.g., having a diameter of about 0.5 mm) and adequate surface is desirable to ensure attachment of sufficient numbers of colonies to produce a quantitative cell response. In numerous embodiments, an article 100 has a well 50 having a uniformly coated surface 15, where the surface 15 has an area greater than about 0.1 cm2, greater than about 0.3 cm2, greater than about 0.9 cm , or greater than about 1cm .
In various embodiments, synthetic polymer surface is deposited on a surface of an intermediate layer that is associated with the base material via covalent or non-covalent interactions, either directly or via one or more additional intermediate layers (not shown). In such embodiments, the intermediate layer will be referred to herein as the “substrate” onto which the synthetic polymer surface is deposited. 12 0043] In various embodiments, the surface of the base material is treated. The surface may be treated to improve binding of the synthetic polymer surface to the base material surface, to facilitate monomer spreading on the base material surface, or the like. Of course, the base material may be treated for similar purposes with regard to an intermediate layer. In various embodiments, the surface is corona treated or vacuum plasma treated. High surfaces energy obtainable from such treatments may facilitate monomer spreading and uniform coating. Examples of vacuum plasma treatment that may be employed include microwave vacuum plasma treatments and radio frequency vacuum plasma treatments. The vacuum plasma treatments may be performed in the presence of reactive gases, such as oxygen, nitrogen, ammonia or nitrous oxide. 2015203433 22 Jun2015 0044] To form the synthetic polymer surface, one or more monomers presented in Table 1 above are polymerized. If one monomer is used, the polymer will be referred to as a homopolymer of the monomer. If two or more different monomers are used, the polymer will be referred to as a copolymer of the monomers. The monomers employed may be monofunctional, difunctional, or higher-functional. When two or more monomers are used, the ratio of the monomers may be varied. In various embodiments, two monomers are used and the ratio, by volume of the first monomer to the second monomer ranges from between about 5:95 to about 95:5. For example, the ratio of the first monomer to the second monomer ranges from between about 10:90 to about 90:10, about 20:80 to about 80:20, from about 30:70 to about 70:30. In some embodiments, the ratio of the first monomer to the second monomer is about 50:50, 30:70, or 10:90. It will be understood that the degree of cross-linking of the polymer may be controlled by varying the concentration of monomers or the ratios of difunctional or higher-functional monomers to monofunctional monomers. Increased concentrations of difunctional or higher-functional monomers will increase the degree of cross-linking in the chains.
[0045] In addition to the monomers that form the polymer layer, a composition forming the layer may include one or more additional compounds such as surfactants, wetting agents, photoinitiators, thermal initiators, catalysts, activators, and cross-linking agents.
[0046] Any suitable polymerization initiator may be employed. One of skill in the art will readily be able to select a suitable initiator, e.g. a radical initiator or a cationic initiator, suitable for use with the monomers listed in Table 1. In various embodiments, UV light is used to generate free radical monomers to initiate chain polymerization. 13 0047] Any suitable initiator may be used. Examples of polymerization initiators include organic peroxides, azo compounds, quinones, nitroso compounds, acyl halides, hydrazones, mercapto compounds, pyrylium compounds, imidazoles, chlorotriazines, benzoin, benzoin alkyl ethers, diketones, phenones, or mixtures thereof. Examples of suitable commercially available, ultraviolet-activated and visible light-activated photoinitiators have tradenames such as IRGACURE 651, IRGACURE 184, IRGACURE 369, IRGACURE 819, DAROCUR 4265 and DAROCUR 1173 commercially available from Ciba Specialty Chemicals, Tarrytown, N.Y. and LUCIRIN TPO and LUCIRIN TPO-L commercially available from BASF (Charlotte, N.C.) 2015203433 22 Jun2015 0048] A photosensitizer may also be included in a suitable initiator system. Representative photosensitizers have carbonyl groups or tertiary amino groups or mixtures thereof. Photosensitizers having a carbonyl group include benzophenone, acetophenone, benzil, benzaldehyde, o-chlorobenzaldehyde, xanthone, thioxanthone, 9,10-anthraquinone, and other aromatic ketones. Photosensitizers having tertiary amines include methyldiethanolamine, ethyldiethanolamine, triethanolamine, phenylmethyl-ethanolamine, and dimethylaminoethylbenzoate. Commercially available photosensitizers include QUANTICURE ITX, QUANTICURE QTX, QUANTICURE PTX, QUANTICURE EPD from Biddle Sawyer Corp. 0049] In general, the amount of photosensitizer or photoinitiator system may vary from about 0.01 to 10% by weight. ^0050] Examples of cationic initiators include salts of onium cations, such as arylsulfonium salts, as well as organometallic salts such as ion arene systems.
[0051] In various embodiments where the monomers are diluted in solvent before being deposited on the substrate surface, the solvent is removed prior to polymerizing. The solvent may be removed by any suitable mechanism or process. As described in copending application serial no. _, it has been found that removal of substantially all of the solvent prior to curing, allows for better control of curing kinetics and the amount of monomer converted. When conversion rates of the monomers are increased, waste generation and cytotoxicity are reduced.
[0052] Whether polymerized in bulk phase (substantially solvent free) or solvent phase, the monomers are polymerized via an appropriate initiation mechanism. Many of such 14 mechanisms are well known in the art. For example, temperature may be increased to activate a thermal initiator, photoinitiators may be activated by exposure to appropriate wavelength of light, or the like. According to numerous embodiments, the monomer or monomer mixture is cured using UV light. The curing preferably occurs under inert gas protection, such as nitrogen protection, to prevent oxygen inhibition. Suitable UV light combined with gas protection may increase polymer conversion, insure coating integrity and reduce cytotoxicity. 2015203433 22 Jun2015 0053] The cured synthetic polymer layer may be washed with solvent one or more times to remove impurities such as unreacted monomers or low molecular weight polymer species. In various embodiments, the layer is washed with an ethanol solvent, e.g. 70% ethanol, greater than about 90% ethanol, greater than about 95% ethanol, or greater than about 99% ethanol. Washing with an ethanol solvent may not only serve to remove impurities, which may be cytotoxic, but also can serve to sterilize the surface prior to incubation with cells.
[0054] 3. Incubating cells on synthetic polymer layer [0055] Stem cell-derived OPCs may be cultured on a synthetic polymer layer, as described above, according to any suitable protocol. As used herein, “stem cell derived OPC” means an OPC obtained from differentiation of a stem cell. In some embodiments, the stem cells are multipotent, totipotent, or pluripotent stem cells. The stem cells may be present in an organ or tissue of a subject. In numerous embodiments, the stem cells are embryonic stem cells, such as human embryonic stem cells. As used herein, “OPC” or “oligodendrocyte progenitor cell” means precursor cells to myelin-forming oligodendrocytes .
[0056] Because human embryonic stem cells (hESC) have the ability to grown continually in culture in an undifferentiated state, the hESC for use in this invention may be obtained from an established cell line. Examples of human embryonic stem cell lines that have been established include, but are not limited to, HI, H7, H9, H13 or HI4 (available from WiCell established by the University of Wisconsin) (Thompson (1998) Science 282:1145 ); hESBGN-01, hESBGN-02, hESBGN-03 (BresaGen, Inc., Athens, GA); HES-1, HES-2, HES-3, HES-4, HES-5, HES-6 (from ES Cell International, Inc., Singapore); HSF-1, HSF-6 (from University of California at San Francisco); I 3,1 3.2,1 3.3,1 4,1 6,1 6.2, J 3, 15 J 3.2 (derived at the Technion-Israel Institute of Technology, Haifa, Israel); UCSF-1 and UCSF-2 (Genbacev et al., Fertil. Steril. 83(5):1517-29, 2005); lines HUES 1-17 (Cowan et al., NEJM 350(13):1353-56, 2004); and line ACT-14 (Klimanskaya et al., Lancet, 365(9471):1636-41, 2005). Embryonic stem cells used in the invention may also be obtained directly from primary embryonic tissue. Typically this is done using frozen in vitro fertilized eggs at the blastocyst stage, which would otherwise be discarded. 2015203433 22 Jun2015 [0057] OPCs according to the invention may also be differentiated from induced primate pluripotent stem (iPS) cells. iPS cells refer to cells, obtained from a juvenile or adult mammal, such as a human, that are genetically modified, e.g., by transfection with one or more appropriate vectors, such that they are reprogrammed to attain the phenotype of a pluripotent stem cell such as an hESC. Phenotypic traits attained by these reprogrammed cells include morphology resembling stem cells isolated from a blastocyst as well as surface antigen expression, gene expression and telomerase activity resembling blastocyst derived embryonic stem cells. The iPS cells typically have the ability to differentiate into at least one cell type from each of the primary germ layers: ectoderm, endoderm and mesoderm and thus are suitable for differentiation into OPCs. The iPS cells, like hESC, also form teratomas when injected into immuno-deficient mice, e.g., SCID mice. (Takahashi et al., (2007) Cell 131(5):861; Yu et al., (2007) Science318:5858).
[0058] [0059] Stem cell derived OPCs may be obtained by any suitable methods. One way to obtain such cells is described in Zhang et al.., “Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors, Stem Cells and Development, 15: 943-952 (2006), citing Nistor et al., Human embryonic stem cells differentiate into oligodendrocytes in high purity and mylenate after spinal cord transplantation, Glia 49: 385-396 (2005). Briefly, undifferentiated human embryonic stem cells, such as those derived from the HI or H7 human embryonic stem cell lines, may be cultured on MATRIGEL-coated plates in mouse embryonic fibroblast (MEF) conditioned medium (CM) supplemented with about 8 ng/ml fibroblast growth factor-2 (FGF-2) or in a chemically defined medium, such as X-VIVO 10 from Cambrex, supplemented with about 80 ng/ml FGF-2 and 0.5 ng/ml transforming growth factor-βΐ (TGF-βΙ). To induce differentiation, the protocol described by Nistor et al. may be employed. Briefly, the human embryonic stem cells may be collagenase digested, scraped, and cultured in 16 defined medium supplemented with insulin, transferrin, progesterone, putrescin, selenium, triiodothyroidin and B27 for 28 days on an ultra-low-attachment plate. The cells may then be cultured in the defined medium for an additional 14 days on growth-factor reduced MATRIGEL. The cells may then be treated with FGF-2, epidermal growth factor (EGF) and all-trans retinoic acid on specified days during differentiation. Differentiation may occur over a number of days, such as 42 days. Of course, any other suitable method may be employed. 2015203433 22 Jun2015 0060] Prior to seeding cells, the cells may be harvested and suspended in a suitable medium, such as a growth medium in which the cells are to be cultured once seeded onto the surface. For example, the cells may be suspended in and cultured in serum-containing medium, a conditioned medium, or a chemically-defined medium. As used herein, “chemically-defined medium” means cell culture media that contains no components of unknown composition. Chemically defined media may, in various embodiments, contain no proteins, hydrosylates, or peptides of unknown composition. In some embodiments, conditioned media contains polypeptides or proteins of known composition, such as recombinant growth hormones. Because all components of chemically-defined media have a known chemical structure, variability in culture conditions and thus cell response can be reduced, increasing reproducibility. In addition, the possibility of contamination is reduced. Further, the ability to scale up is made easier due, at least in part, to the factors discussed above. 0061] The cells may be seeded at any suitable concentration. Typically, the cells are seeded at about 10,000 cells/cm2 of substrate to about 500,000 cells/cm2. For example, cells may be seeded at about 50,000 cells/cm2 of substrate to about 150,000 cells/cm2. However, higher and lower concentrations may readily be used. The incubation time and conditions, such as temperature CO2 and O2 levels, growth medium, and the like, will depend on the nature of the cells being cultured and can be readily modified. The amount of time that the cells are incubated on the surface may vary depending on the cell response being studied or the cell response desired.
[0062] Any suitable method may be used, if desired, to confirm that the stem cell derived OPCs are indeed OPCs or that the stem cells employed have successfully differentiated into OPCs. For example, the presence of certain OPC-selective markers may be investigated, Such markers include Nestin, Oligol, platelet derived growth factor receptor alpha 17 (PDGFRa) and NG2. Antibodies to such markers may be used in standard immunocytochemical or flow cytometry techniques. In addition or alternatively, cellular morphology or production of growth factors detectable in the medium may be evaluated. For example, cultured OPCs may produce one or more of activin A, HGF, midkine, and TGF-P2, which may be detectable in the culture medium via standard assays, such as ELISA. 2015203433 22 Jun2015 0063] The cultured stem cell derived OPCs may be used for any suitable purpose, including investigational studies in culture, in animals, for developing therapeutic uses, or for therapeutic purposes. One potential therapeutic or investigational purpose is repairing damage due to spinal cord injury. 0064] In the following, non-limiting examples are presented, which describe various embodiments of the articles and methods discussed above.
EXAMPLES 0065] EXAMPLE 1: Identification of Acrylic Coating Surfaces Suitable for Culturing Stem
Cell Derived OPCs in a Chemically Defined Medium )066] 1. Coating Preparation 3067] Acrylic coating surfaces were prepared from homomonomers or copolymers of various acrylate monomers. For copolymers two different acrylate monomers were used. A total of 24 homopolymer and 552 copolymer combinations were applied in wells. Briefly, the monomers were diluted in ethanol, and IRGACURE 819 photoinitiator to the ratio of 1:9:0.01 (monomer[volume]/ethanol[volume] /photoinitiator[weight]) to prepare the formulation. For copolymers, two different monomers were mixed with the volume ratio of 70:30 or 30:70. In copolymer formulation, total monomers[volume]/ethanol[volume]/photoinitiator[weight] still remain the ratio of 1:9:0.01. The formulations were placed in a well of a plasma treated cyclic olefin copolymer 96 well plates (provided by Coming Life Science development group) at a volume of 5 pL using BioTek Precession Microplate Pipetting System. Each well received a predetermined homopolymer or copolymer combination, with some wells 18 being coated with MATRIGEL as a positive control, For the wells coated with acrylate monomers, the ethanol solvent was removed by evaporation at room temperature for 3 hr, which removes >99% of the ethanol. The coatings were then cured with 13mW/cm2 pulsed (100 Hz) UV light (Xenon RC-801) for 1 min in N2 purged box (with fused silica window). After curing, a washing step was taken. Briefly, the surface in each well of 96-well plates was incubated with 200pL of >99% ethanol for lhr followed by 200pL of water for over night to move potential extractables. Finally the surfaces were air dried before sterilization. 2015203433 22 Jun2015 0068] 2. Cell preparation and assays
For hESC-derived OPC, HI hESC colonies were detached using 200 U/ml collagenase IV and transferred to Corning ultra-low-adhesion (ULA) plates to allow the formation of embryoid bodies (EBs). To induce neural differentiation, EBs were treated with epidermal growth factor (EGF), FGF-2 (fibroblast growth factor-2) and retinoic acid (RA) for 9 days following by 18 days treatment with EGF only. (Base medium: defined medium supplemented with insulin, transferrin, progesterone, putrescin, selenium, triiodothyroidin (Sigma), and B27 (Invitrogen)). 0069] At this point two different acrylate re-plating schedules were tested: In the first protocol, on day 28, EBs were re-plated on different acrylic surfaces in 96-well plate or on MATRIGEL-coated wells as positive control. Seven days later (day 35), cells were fixed with 4% PFA. In the second protocol, on day 28, EBs were re-plated on MATRIGEL, cultured for 7 days and then (day 35) re-plated on different acrylic surfaces in 96-well plate or on MATRIGEL-coated wells as positive control. Seven days later (day 42), cells were fixed with 4% PFA.
[0070] Cells from the both protocols were immunostained for OPC-specific markers, Nestin, Oligl, and counterstained with 4'-6-Diamidino-2-phenylindole DAPI (nuclear stain).
[0071] After scanning each plate with ArrayScan, the following quantitative analyses were performed for the each surface: 1) TNC: total number of cells, based on DAPI positive cell number, 2) TNO: total number of OPC, based on oligl-positive cells. 19 [0072] 3. 2015203433 22 Jun2015
Results [0073] It was found that only a small portion of the tested surfaces supported attachment and cell outgrowth from EBs in chemically defined medium. FIG. 3 are fluorescence images of immunostained hES cell-derived OPC after re-plating on selected acrylate coated surfaces and positive control Matrigel surface between 28-day and 35-day for differentiation. FIG. 4 are fluorescence images of immunostained hES cell-derived OPC after two re-platings on selected acrylate coated surfaces and positive control Matrigel surface between 28-day and 35-day, as well as between 35-day and 42-days for differentiation. The immunostaining images showed that differentiated cells expressed the OPC markers on some acrylate coating surfaces. The staining of the cells grown on the acrylate surfaces was similar to the staining observed in the cells grown on the Martigel control surface. Examples of the coating surfaces which supported differentiated human OPCs in chemically defined medium are listed in Table 2, where the volume ratio of monomer (1) to monomer (2) is 70:30.
Table 2. Example compositions of acrylic polymers which support the culture of hES cell derived OPCs in chemically defined medium.
Polymer ID Monomer(l) Monomer (2) 95-1 Tetra(ethylene glycol) diacrylate 27-1 Tetra(ethylene glycol) diacrylate Neopentyl glycol ethoxylate diacrylate 123-1 Glycerol dimethacrylate Tetra(ethylene glycol) diacrylate 123-2 Glycerol dimethacrylate Tri(ethylene glycol) dimethacrylate 22-1 Glycerol dimethacrylate Di(ethylene glycol) dimethacrylate 22-2 Glycerol dimethacrylate Tetraethylene glycol dimethacrylate 22-3 Glycerol dimethacrylate 1,6-Hexanediol propoxylate diacrylate 24-10 Glycerol dimethacrylate 1,6-Hexanediol ethoxylate diacrylate 28-2 Trifethylene glycol) dimethacrylate Trimethylolpropane triacrylate 28-10 1,4-Butanediol dimethacrylate 1,9 nonanediol diacrylate 36-4 1,6-Hexanediol diacrylate Tricyclo[5.2.1,02,6]decanedimethanol diacrylate 36-5 1,6-Hexanediol diacrylate 1,6-Hexanediol ethoxylate diacrylate 36-6 1,6-Hexanediol diacrylate Neopentyl glycol ethoxylate diacrylate 20 2015203433 22 Jun2015 39-6 Neopentyl glycol propoxylate (1PO/OH) diacrylate Neopentyl glycol ethoxylate diacrylate 133-4 Di(ethylene glycol) dimethacrylate Neopentyl glycol diacrylate 47-4 Di(ethylene glycol) dimethacrylate Tricyclo[5.2.1.0i,f)]decanedimethanol diacrylate 41-9 Tetra(ethylene glycol) dimethacrylate 1,4-Butanediol dimethacrylate 50-6 Tetra(ethylene glycol) dimethacrylate Neopentyl glycol ethoxylate diacrylate 51-1 1,6-Hexanediol propoxylate diacrylate Neopentyl glycol ethoxylate diacrylate 49-4 Neopentyl glycol diacrylate Tricyclo[5.2.1.02’6] decanedi methanol diacrylate 49-5 Neopentyl glycol diacrylate 1,6-Hexanediol ethoxylate diacrylate 52-4 Neopentyl glycol diacrylate Polypropylene glycol) diacrylate 63-3 Trimethylolpropane ethoxylate (1 EO/OH) methyl diacrylate 2,2,3,3,4,4,5,5 octafluoro 1, 6 hexanediol diacrylate 71-1 Neopentyl glycol ethoxylate diacrylate Di(ethylene glycol) dimethacrylate 65-9 T rimethylolpropane triacrylate 1,4-Butanediol dimethacrylate 71-6 Trimethylolpropane triacrylate Di(ethylene glycol) dimethacrylate 71-10 T rimethylolpropane triacrylate Neopentyl glycol diacrylate 74-6 T rimethylolpropane triacrylate Neopentyl glycol dimethacrylate 72-2 2,2,3,3,4,4,5,5 octafluoro 1, 6 hexanediol diacrylate Tetra(ethylene glycol) dimethacrylate 72-5 2,2,3,3,4,4,5,5 octafluoro 1, 6 hexanediol diacrylate Neopentyl glycol diacrylate 72-9 Polypropylene glycol) diacrylate Glycerol 1,3-diglycerolate diacrylate [0074] Figures 5A-F show images taken from micrographs of hESC derived OPCs growing on Matrigel ™ as a positive control and selected embodiments of surfaces of the present invention; 22-2 (B), 22-3 (C), 133-4 (D), 24-10 (E), and 72-2 (F). Figures 5A-F show nuclear staining on hESC derived OPCs on Matrigel or the above-referenced embodiments of surfaces of the present invention stained with Hoecst nuclear stain. Figures 5A-F illustrate that embodiments of surfaces of the present invention provide suitable surfaces to support adhesion and growth of hESC derived OPCs in chemically 21 defined medium. For other tested homopolymers and copolymer combinations, that is those combinations that are not listed in Table 2 above, no EB attachment to the surface or cell outgrows from the EBs was observed. 2015203433 22 Jun2015 0075] Thus, embodiments of SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED OLIGODENDROCYTE PROGENITOR CELLS are disclosed. One skilled in the art will appreciate that the arrays, compositions, kits and methods described herein can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation. 22
Claims (5)
- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:1. A cell culture comprising: 1) an oligodendrocyte progenitor cell disposed on a polymer material, wherein the polymer material comprises an acrylate or a diaerylate; and 2) a culture medium.
- 2. The cell culture of claim 1, wherein the oligodendrocyte progenitor cell is a human oligodendrocyte progenitor cell.
- 3. Tile cell culture of claim L wherein the oligodendrocyte progenitor cell is derived from a human embryonic stem cell.
- 4. The cell culture of claim 1, wherein the oligodendrocyte progenitor cell is derived from an induced pluripotent stem ceil.
- 5. The cell culture according to any one of claims I to 4, wherein the oligodendrocyte progenitor cell expresses one or more markers selected from Nestin, Oligl, platelet derived growth factor receptor alpha (PDGFRa) and NG2.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015203433A AU2015203433B2 (en) | 2008-01-30 | 2015-06-22 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2017204415A AU2017204415A1 (en) | 2008-01-30 | 2017-06-28 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2019226172A AU2019226172A1 (en) | 2008-01-30 | 2019-09-04 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6301008P | 2008-01-30 | 2008-01-30 | |
| US61/063,010 | 2008-01-30 | ||
| PCT/US2009/032425 WO2009097421A1 (en) | 2008-01-30 | 2009-01-29 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2009209167A AU2009209167B8 (en) | 2008-01-30 | 2009-01-29 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2015203433A AU2015203433B2 (en) | 2008-01-30 | 2015-06-22 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009209167A Division AU2009209167B8 (en) | 2008-01-30 | 2009-01-29 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017204415A Division AU2017204415A1 (en) | 2008-01-30 | 2017-06-28 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015203433A1 AU2015203433A1 (en) | 2015-07-16 |
| AU2015203433B2 true AU2015203433B2 (en) | 2017-04-06 |
Family
ID=53673349
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015203433A Ceased AU2015203433B2 (en) | 2008-01-30 | 2015-06-22 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2017204415A Abandoned AU2017204415A1 (en) | 2008-01-30 | 2017-06-28 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2019226172A Abandoned AU2019226172A1 (en) | 2008-01-30 | 2019-09-04 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017204415A Abandoned AU2017204415A1 (en) | 2008-01-30 | 2017-06-28 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| AU2019226172A Abandoned AU2019226172A1 (en) | 2008-01-30 | 2019-09-04 | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
Country Status (1)
| Country | Link |
|---|---|
| AU (3) | AU2015203433B2 (en) |
-
2015
- 2015-06-22 AU AU2015203433A patent/AU2015203433B2/en not_active Ceased
-
2017
- 2017-06-28 AU AU2017204415A patent/AU2017204415A1/en not_active Abandoned
-
2019
- 2019-09-04 AU AU2019226172A patent/AU2019226172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015203433A1 (en) | 2015-07-16 |
| AU2019226172A1 (en) | 2019-09-26 |
| AU2017204415A1 (en) | 2017-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2714010C (en) | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells | |
| EP2247718B1 (en) | Synthetic surfaces for culturing stem cell derived cardiomyocytes | |
| AU2015203433B2 (en) | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells | |
| HK1148546A (en) | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells | |
| HK1148546B (en) | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells | |
| HK1152727A (en) | Synthetic surfaces for culturing stem cell derived cardiomyocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |